These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 21246222)

  • 21. Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
    Rockwood K; Howlett SE; Hoffman D; Schindler R; Mitnitski A
    Alzheimers Dement; 2017 Oct; 13(10):1098-1106. PubMed ID: 28341540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
    Aronson S; Van Baelen B; Kavanagh S; Schwalen S
    Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease.
    Sabbagh M; Sadowsky C; Tousi B; Agronin ME; Alva G; Armon C; Bernick C; Keegan AP; Karantzoulis S; Baror E; Ploznik M; Pascual-Leone A
    Alzheimers Dement; 2020 Apr; 16(4):641-650. PubMed ID: 31879235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C; Minthon L; Wallin ÅK
    Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
    Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
    J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
    Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
    Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
    Erkinjuntti T; Kurz A; Small GW; Bullock R; Lilienfeld S; Damaraju CV;
    Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
    Small G; Erkinjuntti T; Kurz A; Lilienfeld S
    CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine.
    Shirayama Y; Takahashi M; Oda Y; Yoshino K; Sato K; Okubo T; Iyo M
    Brain Imaging Behav; 2019 Feb; 13(1):75-86. PubMed ID: 29247294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of simultaneous rTMS-tDCS over bilateral angular gyrus on neuropsychiatric symptoms in patients with moderate Alzheimer's disease: A prospective, randomized, sham-controlled pilot study.
    Hu Y; Jia Y; Sun Y; Ding Y; Huang Z; Liu C; Wang Y
    Brain Stimul; 2022; 15(6):1530-1537. PubMed ID: 36460293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
    Rockwood K; Dai D; Mitnitski A
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
    Chu LW; Yik PY; Mok W; Chung CP
    Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
    Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of rTMS treatment on global cognitive function in Alzheimer's disease: A systematic review and meta-analysis.
    Zhang T; Sui Y; Lu Q; Xu X; Zhu Y; Dai W; Shen Y; Wang T
    Front Aging Neurosci; 2022; 14():984708. PubMed ID: 36158564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repetitive Transcranial Magnetic Stimulation With H-Coil in Alzheimer's Disease: A Double-Blind, Placebo-Controlled Pilot Study.
    Leocani L; Dalla Costa G; Coppi E; Santangelo R; Pisa M; Ferrari L; Bernasconi MP; Falautano M; Zangen A; Magnani G; Comi G
    Front Neurol; 2020; 11():614351. PubMed ID: 33679572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks.
    Bowen RL; Perry G; Xiong C; Smith MA; Atwood CS
    J Alzheimers Dis; 2015; 44(2):549-60. PubMed ID: 25310993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Galantamine treatment in outpatients with mild Alzheimer's disease.
    Richarz U; Gaudig M; Rettig K; Schauble B
    Acta Neurol Scand; 2014 Jun; 129(6):382-92. PubMed ID: 24461047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer's dementia.
    Ahmed MA; Darwish ES; Khedr EM; El Serogy YM; Ali AM
    J Neurol; 2012 Jan; 259(1):83-92. PubMed ID: 21671144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
    Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
    J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
    Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.